Long‐term results with cisapride in Parkinson's disease
Identifieur interne : 003591 ( Istex/Corpus ); précédent : 003590; suivant : 003592Long‐term results with cisapride in Parkinson's disease
Auteurs : Jost ; Klaus SchimrigkSource :
- Movement Disorders [ 0885-3185 ] ; 1997-05.
English descriptors
- KwdEn :
Abstract
In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.
Url:
DOI: 10.1002/mds.870120324
Links to Exploration step
ISTEX:E8BF946E8AA98C2E2E6383757C47A69393C4AA69Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term results with cisapride in Parkinson's disease</title><author><name sortKey="Jost" sort="Jost" uniqKey="Jost" last="Jost">Jost</name><affiliation><mods:affiliation>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schimrigk, Klaus" sort="Schimrigk, Klaus" uniqKey="Schimrigk K" first="Klaus" last="Schimrigk">Klaus Schimrigk</name><affiliation><mods:affiliation>University of Saarland, Homburg/Saar, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E8BF946E8AA98C2E2E6383757C47A69393C4AA69</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120324</idno><idno type="url">https://api.istex.fr/document/E8BF946E8AA98C2E2E6383757C47A69393C4AA69/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003591</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term results with cisapride in Parkinson's disease</title><author><name sortKey="Jost" sort="Jost" uniqKey="Jost" last="Jost">Jost</name><affiliation><mods:affiliation>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</mods:affiliation></affiliation></author><author><name sortKey="Schimrigk, Klaus" sort="Schimrigk, Klaus" uniqKey="Schimrigk K" first="Klaus" last="Schimrigk">Klaus Schimrigk</name><affiliation><mods:affiliation>University of Saarland, Homburg/Saar, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-05">1997-05</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="423">423</biblScope><biblScope unit="page" to="425">425</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E8BF946E8AA98C2E2E6383757C47A69393C4AA69</idno><idno type="DOI">10.1002/mds.870120324</idno><idno type="ArticleID">MDS870120324</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cisapride</term><term>Constipation</term><term>Parkinson's disease</term><term>Treatment</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. med. Jost</name><affiliations><json:string>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</json:string></affiliations></json:item><json:item><name>Klaus Schimrigk</name><affiliations><json:string>University of Saarland, Homburg/Saar, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Constipation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Cisapride</value></json:item></subject><language><json:string>eng</json:string></language><abstract>In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.</abstract><qualityIndicators><score>3.038</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 827.759 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>803</abstractCharCount><pdfWordCount>1406</pdfWordCount><pdfCharCount>8548</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>136</abstractWordCount></qualityIndicators><title>Long‐term results with cisapride in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>12</volume><pages><total>3</total><last>425</last><first>423</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1997</publicationDate><copyrightDate>1997</copyrightDate><doi><json:string>10.1002/mds.870120324</json:string></doi><id>E8BF946E8AA98C2E2E6383757C47A69393C4AA69</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E8BF946E8AA98C2E2E6383757C47A69393C4AA69/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E8BF946E8AA98C2E2E6383757C47A69393C4AA69/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E8BF946E8AA98C2E2E6383757C47A69393C4AA69/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Long‐term results with cisapride in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>1997</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Long‐term results with cisapride in Parkinson's disease</title><author><persName><surname>Jost</surname><roleName type="degree">Dr. med.</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Aukammallee 33, D‐65191 Wiesbaden, Germany</p></note><affiliation>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</affiliation></author><author><persName><forename type="first">Klaus</forename><surname>Schimrigk</surname></persName><affiliation>University of Saarland, Homburg/Saar, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-05"></date><biblScope unit="vol">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="423">423</biblScope><biblScope unit="page" to="425">425</biblScope></imprint></monogr><idno type="istex">E8BF946E8AA98C2E2E6383757C47A69393C4AA69</idno><idno type="DOI">10.1002/mds.870120324</idno><idno type="ArticleID">MDS870120324</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1997</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Constipation</term></item><item><term>Treatment</term></item><item><term>Cisapride</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996-03-11">Received</change><change when="1996-10-19">Registration</change><change when="1997-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E8BF946E8AA98C2E2E6383757C47A69393C4AA69/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v12:3</doi><numberingGroup><numbering type="journalVolume" number="12">12</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="1997-05">May 1997</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="24" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870120324</doi><idGroup><id type="unit" value="MDS870120324"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1997 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1996-03-11"></event><event type="manuscriptRevised" date="1996-09-01"></event><event type="manuscriptAccepted" date="1996-10-19"></event><event type="firstOnline" date="2004-11-04"></event><event type="publishedOnlineFinalForm" date="2004-11-04"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">423</numbering><numbering type="pageLast">425</numbering></numberingGroup><correspondenceTo>Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Aukammallee 33, D‐65191 Wiesbaden, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870120324.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="8"></count></countGroup><titleGroup><title type="main" xml:lang="en">Long‐term results with cisapride in Parkinson's disease</title><title type="short" xml:lang="en">LONG‐TERM CISAPRIDE IN PARKINSON'S DISEASE</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr. med.</honorifics><givenNames>Wolfgang H.</givenNames><familyName>Jost</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Klaus</givenNames><familyName>Schimrigk</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>University of Saarland, Homburg/Saar, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Constipation</keyword><keyword xml:id="kwd3">Treatment</keyword><keyword xml:id="kwd4">Cisapride</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Long‐term results with cisapride in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>LONG‐TERM CISAPRIDE IN PARKINSON'S DISEASE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Long‐term results with cisapride in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr. med.</namePart><namePart type="family">Jost</namePart><affiliation>Departments of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany</affiliation><description>Correspondence: Department of Neurology and Clinical Neurophysiology, Deutsche Klinik für Diagnostik, Aukammallee 33, D‐65191 Wiesbaden, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Schimrigk</namePart><affiliation>University of Saarland, Homburg/Saar, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1997-05</dateIssued><dateCaptured encoding="w3cdtf">1996-03-11</dateCaptured><dateValid encoding="w3cdtf">1996-10-19</dateValid><copyrightDate encoding="w3cdtf">1997</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">8</extent></physicalDescription><abstract lang="en">In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Constipation</topic><topic>Treatment</topic><topic>Cisapride</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>423</start><end>425</end><total>3</total></extent></part></relatedItem><identifier type="istex">E8BF946E8AA98C2E2E6383757C47A69393C4AA69</identifier><identifier type="DOI">10.1002/mds.870120324</identifier><identifier type="ArticleID">MDS870120324</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1997 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003591 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003591 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E8BF946E8AA98C2E2E6383757C47A69393C4AA69
|texte= Long‐term results with cisapride in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |